Inteligex is a cell therapy company focused on solving currently incurable conditions of the central nervous system.
Our Founder @DrFehlings leading the 2022 Basic-Translational-Clinical Roundtable: Advancing Treatments to Drive Functional Restoration After Spinal Cord Injury: Developing a Pathway to Facilitate the Translational Pipeline at @SfN_Events !!
It was great to have an opportunity to speak at the @SfN_Events '2022 Basic-Translational-Clinical Roundtable: Advancing Treatments to Drive Functional Restoration After Spinal Cord Injury: Developing a Pathway to Facilitate the Translational Pipeline'! @KBI_UHN @UofTSpine #SCI
It is great to be over in Israel as part of the @UTESTto Innovation and Entrepreneurial Exchange Program! #innovation #celltherapy2
Congrats @Inteligex founder & @UofT Prof, @DrFehlings. He recently received:
🔹 2022 Apple award for excellence in spinal cord injury (SCI) rehabilitation literature
🔹@Nature's #1 author in the world for articles relevant to #SCI in the last 20 years
Inteligex Founding Member and CSO Dr. Mamad Khazaei recently won the Best Oral Presentation Award at the International Neurotrauma Symposium in Berlin!
Congratulations to Dr. Mamad Khazaei on receiving the Best Oral Presentation Award at the @neurotrauma2022 meeting in Berlin!! @UofTSpine @KBI_UHN @inteligex
I was fortunate to have the opportunity to be President of the International Neurotrauma Society and to organize the meeting in Toronto in 2018. It is great to be meeting in person in Berlin at another great INTS meeting. More updates to follow! @UofTSpine @KBI_UHN
We are excited to be a part of this important @praxis_sci program that helps bring exciting new products to those living with spinal cord injuries. Stay tuned for more updates!
Please join us in welcoming our 2022 Praxis #SCIAccelerate cohort! Praxis is pleased to announce four companies that will spend the next few months working closely with Praxis' commercialization, consumer and research teams. https://praxisinstitute.org/praxis-sci-accelerate-2022-cohort/
Congratulations Dr. Ahuja!!
A huge congratulations to @SuganthSuppiah, @jetanbadhiwala, and Dr. Chris Ahuja for successfully completing your Royal College exams!
#Neurosurgery #Neurosurgeon #RoyalCollege
A great recent publication discussing cell-based therapies for spinal cord injury, including lessons learned from clinical trials. It is an exciting era and we are proud to be at the forefront of this work. https://authors.elsevier.com/c/1f3d55FFzKqoTc
Exciting to see this @ELSneuroscience textbook, led by Inteligex Founder Dr. Michael Fehlings, published! This book will be the go-to resource on spinal cord injury and spine trauma for years to come! #spinalcordinjury #SCI #trauma
Excited to announce that our book "Neural Repair and Regeneration after Spinal Cord Injury and Spine Trauma" is now published!! Thanks to everyone who contributed to this book and the @ELSneuroscience team for supporting us!!
This year's @OBIOscience Investment Summit features #UHNStartups @MedlyHF, an innovation in cardiac health, and, in partnership with @StemCellNetwork, @Inteligex2, a @UHN company currently developing stem cell therapeutics for spinal cord injury. https://twitter.com/OBIOscience/status/1486412387615977473
We are excited to announce new additions to the Early Technology Showcase at the #OBIOInvestmentSummit, on February 9-11! The Early Technology Showcase features nine of Canada’s leading research organizations. Here is a snapshot of what you will see: https://bit.ly/ETS2022